Clinical trial NCT00392665 (phase 2, status: terminated)
Conditions: squamous cell carcinoma of the head and neck (scchn)
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: bevacizumab, erlotinib, sulindac
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically documented SCCHN, excluding salivary gland primary sites

          -  18 years of age or older

          -  Have evaluable locoregional and/or metastatic disease according to RECIST that is not
             appropriate for treatment by primary surgical resection or radiotherapy

          -  Have locoregional and/or metastatic disease that has failed to respond to or relapsed
             from at least one prior chemotherapy or chemoradiotherapy

          -  Life expectancy of at least 4 months

          -  ECOG performance status of 0-2

          -  Use of effective means of contraception in patients of child-bearing potential

        Exclusion Criteria:

          -  Other malignancy within 5 years except non-melanomatous skin cancer, or carcinoma in
             situ of the cervix, bladder or head and neck

          -  Concurrent anticancer therapy other than that of this study

          -  Treatment with any anticancer drug within 28 days of day 1

          -  Radiotherapy within 28 days of day 1

          -  Any unresolved toxicity greater than NCI-CTCAE v 3.0 grade 2 from prior systemic
             anticancer therapy

          -  Any prior therapy that targets the ErbB and/or VEGF pathways

          -  Concurrent therapy with any NSAID

          -  Known hypersensitivity characterized by acute bronchospasm, urticaria and/or rhinitis
             to NSAIDs, including aspirin

          -  Serum creatinine > 1.5 x ULN

          -  Abnormal LFTs as outlined in protocol

          -  Blood pressure > 150/100mmHg

          -  Active unstable angina, or myocardial infarction within 6 months

          -  NYHA Grade II or greater congestive heart failure

          -  History of stroke within 6 months

          -  Clinically significant active peripheral vascular disease

          -  Absolute neutrophil count < 1000/mm3 or platelets < 100,000/mm3

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Tumor encasing the carotid artery, or other major vessel that in the opinion of the
             investigators is at risk for tumor-related hemorrhage

          -  Presence of central nervous system or brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1, or anticipation of need for major surgical procedure during the course
             of the study

          -  Minor surgical procedures such as fine needle aspiration or core biopsy within 5 days
             prior to day 1

          -  Pregnant or lactating

          -  History of abdominal fistula or intra-abdominal abscess within 6 months

          -  History of gastrointestinal ulcer, perforation, or bleeding within 6 months

          -  Serious non-healing wound or ulcer or active uncontrolled infection

          -  Bone fracture within 28 days

          -  Active substance abuse, defined by substance abuse of alcohol, cocaine or intravenous
             drug use within 6 months